

ISV ANNUAL CONGRESS

International
Society for
VACCINES

2026

12 - 14 OCTOBER
A ROOM WITH A ZOO
ANTWERP | BELGIUM

CONGRESS PROGRAM



MONDAY, 12 OCTOBER 2026

08:40-09:40	REGISTRATION & WELCOME COFFEE • <i>sponsored by EuBiologics Co</i>	ATRIUM
09:40-09:50	OPENING SESSION	OKAPI
	WELCOME BY ISV PRESIDENT: Manon Cox, NEXTWAVEBIO, USA CO-CHAIR REMARKS: Michael Schotsaert, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, USA Lakshmi Krishnan, NATIONAL RESEARCH COUNCIL (NRC), CANADA Isabel Leroux-Roels, UNIVERSITY OF GHENT, BELGIUM	
09:50-10:35	STANLEY PLOTKIN LECTURE	OKAPI
	SESSION CHAIR: Manon Cox, NEXTWAVE BIO, USA / ISV PRESIDENT Yellow fever 17D live attenuated vaccine: A great vaccine but how does it work? Alan Barrett, THE UNIVERSITY OF TEXAS MEDICAL BRANCH (UTMB), USA	
10:35-11:55	PLENARY SESSION 1: Population Impact of Vaccination	OKAPI
	SESSION CHAIRS: Sarah Gilbert, UNIVERSITY OF OXFORD, UNITED KINGDOM Joon Haeng Rhee, CHONNAM NATIONAL UNIVERSITY MEDICAL SCHOOL, SOUTH KOREA	
10:35-11:00	Clinical Data for the RSVpreF Vaccine in Older Adults, At-Risk Adults Aged 18-59, and Immunocompromised Adults Kumar Ilangoan, PFIZER VACCINE R & D, USA	
11:00-11:25	Rotavirus Vaccines: Where We Are and What's Next Michelle Groome, UNIVERSITY OF WITWATERSRAND, SOUTH AFRICA	
11:25-11:40	Recombinant Staphylococcus Aureus Vaccine demonstrating 73.25% Protective Efficacy in Phase III clinical study in China Jingxin Li, CHENGDU OLYMVAX BIOPHARMACEUTICALS INC, PEOPLE'S REPUBLIC OF CHINA	
11:40-11:55	Safety and Immunogenicity of a Novel Trivalent Virus-Like Particle Poliovirus Vaccine (VPV): A Phase 1, Randomized, Observer-Blind Trial Qiaolin Yan, CANSINO BIOLOGICS INC., PEOPLE'S REPUBLIC OF CHINA	
11:55-12:05	Why Flanders is a Vaccine Development Hub Kristof Lowyck, DIRECTOR AMERICAS, FLANDERS INVESTMENT & TRADE, BELGIUM	OKAPI
12:05-13:30	LUNCH • <i>sponsored by SANOFI</i>	ATRIUM
12:30-13:30	LUNCH WORKSHOP Defining Immune Evidence Standards for Respiratory Vaccine Development SESSION CHAIR AND MODERATOR: Nnenna Chime, SANOFI, USA PANELISTS: • François Beckers, SANOFI, FRANCE, • Matthew Miller, MCMASTER UNIVERSITY, CANADA, • Fabian Tibaldi, GSK, BELGIUM	OKAPI
13:30-15:05	PLENARY SESSION 2: Mucosal Vaccines	OKAPI
	SESSION CHAIRS: Michael Schotsaert, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, USA Sandra Depelsenaire, VAXXAS, AUSTRALIA	
13:30-13:55	Trans-kingdom Effects on Immunity to Viruses Michael Diamond, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE, USA	
13:55-14:20	Adjuvants - The Tool to Obtain the Required Immune Responses in Vaccination Dennis Christensen, CRODA PHARMA, DENMARK	
14:20-14:35	Charting Mucosal Immune Responses to Influenza using Human Immune-competent Organoids Martin Beukema, UNIVERSITY MEDICAL CENTER GRONINGEN, THE NETHERLANDS	
14:35-14:50	Environmental drivers of oral typhoid vaccine responses in Uganda: dissecting rural–urban differences and the role of Schistosoma mansoni Bridgious Walusimbi, MRC/UVRI AND LSHTM UGANDA RESEARCH UNIT, UGANDA	
14:50-15:05	Inhaled aerosol vaccination with an adenoviral-vectored TB vaccine induces robust respiratory mucosal immunity in humans Sam Afkhami, MCMASTER UNIVERSITY, CANADA	
15:05-15:30	COFFEE BREAK • <i>sponsored by VisMederi</i>	ATRIUM

15:30-17:35	CONCURRENT SESSION 1	CONCURRENT SESSION 2	CONCURRENT SESSION 3
	OKAPI	GORILLA 1	GORILLA 3
	Adjuvants	Vaccine Regulatory Science and Policy	“Bright Sparks” in Vaccinology PhD Student Session
	SESSION CHAIRS: • Ed Lavelle, TRINITY COLLEGE, DUBLIN • Lars Frelin, KAROLINSKA INSTITUTET, SWEDEN	SESSION CHAIRS: • Manon Cox, NEXTWAVE BIO, USA / ISV PRESIDENT • Xuefei Zhou, XZ GMP CONSULTING, USA	SESSION CHAIRS: • Jeffrey Ulmer, TECHIMMUNE LLC, USA • Martin Beukema, UNIVERSITY MEDICAL CENTER GRONINGEN, NETHERLANDS • Alejandra Capozzo, UNIVERSIDAD ABIERTA INTERAMERICANA, ARGENTINA
15:30-15:55	Open-access Adjuvants for Prophylactic Human Vaccines Marcelle Van Mechelen , VACCINE FORMULATION INSTITUTE, SWITZERLAND	Regulatory Acceptance of Immunological Biomarkers as Surrogate for Vaccine Efficacy – Ebola Zaire Vaccine Case Marie-Chantal Uwamwezi , PATH, BELGIUM	Cross-Reactive SARS-CoV-2 Antibodies in Pre-Pandemic Gambian Sera Exhibit Fc-Mediated Effector Activity Dawda Jobe , MRC UNIT THE GAMBIA AT LSHTM, GAMBIA <i>(15:30-15:40)</i> Seroepidemiology and serum bactericidal activity of IgG antibodies to Non Typhoidal Salmonella in healthy Children in Mukuru informal settlement in Kenya Schola Kamwethya , KENYA MEDICAL RESEARCH INSTITUTE, KENYA <i>(15:40-15:50) Switchover Break (15:50-15:55)</i>
15:55-16:20	From Empirical Adjuvants to Programmable Immunity Nathalie Garçon , N3J CONSULTING, BELGIUM	Beyond Efficacy: How Early Development Decisions Shape the Population Impact of Vaccines Beate Sander , UNIVERSITY OF TORONTO, CANADA	The Effect of Malaria Intermittent Preventive Treatment on Vaccine Responses and SARS-CoV-2 Seroprevalence in Adolescents: Findings from a Randomised Controlled Trial Ludoviko Zirimenya , MRC/UVRI & LSHTM UGANDA RESEARCH UNIT, UGANDA <i>(15:55-16:05)</i> APC-Mimetic Dendritic Cell-Derived Extracellular Vesicle Nanovaccine with STING Adjuvant Induces Long-Term Th1 Immunity and Immune Memory Against Dengue Virus Anindita Sengupta , INDIAN INSTITUTE OF TECHNOLOGY, INDIA <i>(16:05-16:15) Switchover Break (16:15-16:20)</i>
16:20-16:35	Antigen cross-presentation potentiating cancer vaccine adjuvant for T cell expansion and synergy with anti-PD-1 Giang Chau Dang , CHONNAM NATIONAL UNIVERSITY, SOUTH KOREA	Primary Healthcare Surveillance and Vaccination Challenges During the 2025 Meningococcal Serogroup C Outbreak Response in Sokoto State, Northern Nigeria Ikechukwu Nnaji , NIGERIA CENTRE FOR DISEASE CONTROL AND PREVENTION (NCDC), NIGERIA	Induction of influenza-specific immunity in pigs using dissolvable microneedle patches to deliver an adenovirus-based vaccine Inés Co Rives , UNIVERSITY COLLEGE CORK, IRELAND <i>(16:20-16:30) Switchover Break (16:30-16:35)</i>
16:35-16:50	Modulation of the bone marrow hematopoietic and immune cell landscape by vaccine adjuvants Eleanor Burgess , ICAHN SCHOOL OF MEDICINE, USA	Immunological assays and correlates of protection: the missing tool for next-generation influenza vaccines Emanuele Montomoli , VISMEDERI SRL, ITALY	Systemic response and short-term functional changes following infection with Necator americanus third-stage infective larvae: Insights from a control human hookworm infection trial in Lambarene, Gabon Therese Vanessa Amana Bokagne , CENTRE DE RECHERCHES MEDICALES DE LAMBARENE, GABONESE REPUBLIC <i>(16:35-16:45) Switchover Break (16:45-16:50)</i>

ISV ANNUAL CONGRESS 2026 • PROGRAMME

	CONCURRENT SESSION 1	CONCURRENT SESSION 2	CONCURRENT SESSION 3
	OKAPI	GORILLA 1	GORILLA 3
16:50-17:05	Neutrophils are the dominant early responders to a potent liposomal vaccine adjuvant Lee Sims , UNIVERSITY OF OXFORD, UNITED KINGDOM	Panel Discussion MODERATOR: Manon Cox , NEXTWAVE BIO, USA / ISV PRESIDENT PANELISTS: • Emanuele Montomoli , VISMEDERI SRL, ITALY • Beate Sander , UNIVERSITY OF TORONTO, CANADA • Marie-Chantal Uwamwezi , PATH, BELGIUM • Xuefei Zhou , XZ GMP CONSULTING, USA	Intranasal protein-based vaccines protect against 2.3.4.4b H5N1 infection in young and old BALB/C mice Gabriel Laghlali , ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, USA
17:05-17:20	GVX-PA-01, a novel Pseudomonas aeruginosa (Pa) vaccine Elodie Pastural , GLYCOVAX PHARMA, CANADA		A simplified and sensitive assay for tracking virus-specific T cell responses in the nasal cavity during SARS-CoV-2 human challenge studies Previtha Dawn Sakthi Vale , NATIONAL UNIVERSITY OF SINGAPORE, SINGAPORE
17:20-17:35	PIV5-Vectored Intranasal RSV Vaccine is Safe and Immunogenic in Infants and Young Children Biao He , BLUE LAKE BIOTECHNOLOGY, INC/ CYANVAC LLC, USA		AI-Driven Infodemic Surveillance and Its Impact on COVID-19 Vaccine Uptake in Sub-Saharan Africa: A Multi-Country Study Angyiba Serge Andigema , DEPARTMENT OF RESEARCH, BISON'S SCHOLARS, DOUALA, CAMEROON
17:35-20:00	POSTER SESSION 1 • sponsored by PFIZER		ATRIUM
17:35-20:00	WELCOME RECEPTION • sponsored by BHARAT BIOTECH		ATRIUM

TUESDAY, 13 OCTOBER 2026

08:00-08:30	WELCOME COFFEE • sponsored by MODERNA	ATRIUM
08:30-09:00	KEYNOTE SPEAKER	OKAPI
	SESSION CHAIR: Michael Schotsaert , ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, USA From Preclinical Insight to Clinical Evidence: Advancing the Next Generation of Pneumococcal Conjugate Vaccines Annaliesa Anderson , PFIZER, USA	
09:00-10:30	PLENARY SESSION 3: Vaccine Technology	OKAPI
	SESSION CHAIRS: Indresh Srivastava , NOVAVAX, USA Linda Lua , THE UNIVERSITY OF QUEENSLAND & THE GROWTH IMPACT, AUSTRALIA	
09:00-09:25	Beyond the Needle - Discussing the Future of Vaccine Technologies Tarit Mukhopadhyay , MERCK, USA	
09:25-09:50	Advancing Therapeutic Vaccines Through Clinically Validated LNP Delivery Technologies Xiangrong Song , WESTGENE BIOPHARMA, CHINA	
09:50-10:15	Exploring New Paradigms in Vaccine Landscape Emilio Fumero , MODERNA, SPAIN	
10:15-10:30	Safety, Reactogenicity and Immunogenicity of a Launch-IT Rabies Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study in Healthy Adults Lidia Oostvogels , ASTRIVAX THERAPEUTICS, BELGIUM	
10:30-11:00	KEYNOTE SPEAKER (VIRTUAL)	OKAPI
	SESSION CHAIR: Lakshmi Krishnan , NATIONAL RESEARCH COUNCIL (NRC), CANADA Entering the Vaccine Space During Uncertain Times Peter Marks , ELI LILLY AND COMPANY, USA	
11:00-11:20	COFFEE BREAK • sponsored by ARCTURUS THERAPEUTICS	ATRIUM

11:20-12:55	CONCURRENT SESSION 4	CONCURRENT SESSION 5	CONCURRENT SESSION 6
OKAPI	GORILLA 1	GORILLA 3	
	Immunotherapies	Vaccines for Vector-borne Diseases	“Bright Sparks” in Vaccinology ECR Session
	SESSION CHAIRS: • Lenny Moise, SEROMYX, USA • Annie de Groot, EVA Therapeutics, USA	SESSION CHAIRS: • Kai Dallmeier, KU LEUVEN, BELGIUM • Alba Grifoni, LA JOLLA INSTITUTE FOR IMMUNOLOGY, USA	SESSION CHAIRS: • Barbara Felber, NCI/NIH, USA • Valentino D’Onofrio, GHENT UNIVERSITY, BELGIUM • Denise Doolan, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA
11:20-11:45	Unleashing our innate immune system as defense against disease Joost Kreijtz , TRAINED THERAPEUTIC DISCOVERY (TTXD), NETHERLANDS	From Efficacy to Impact: What We Can Learn About Dengue Vaccination From TAK-003, a Tetravalent Dengue Vaccine Liudmyla Budovska , TAKEDA PHARMACEUTICALS INTERNATIONAL AG, SWITZERLAND	Effectiveness of PCV10 and PCV13 against invasive pneumonia disease in vietnamese children prior to national introduction: a matched case-control study Cong Hieu Truong , PASTEUR INSTITUTE IN HO CHI MINH CITY, VIETNAM <i>(11:20-11:30)</i> Age-specific immunity gaps and residual susceptibility to measles and rubella before and after the measles–rubella supplementary immunisation campaign in South India Ramya Madhavan , CHRISTIAN MEDICAL COLLEGE, INDIA <i>(11:30-11:40) Switchover Break (11:40-11:45)</i>
11:45-12:10	Antibody effector functions in antiviral immunity Taia Wang , STANFORD UNIVERSITY SCHOOL OF MEDICINE, USA	Controlled human infection studies to accelerate vaccine development Meta Roestenberg , LEIDEN UNIVERSITY, NETHERLANDS	Antigen composition, not T-cell functionality, limits cross-reactivity to distant Coronaviruses after bivalent SARS2 Spike vaccination Ziyin Wang , LA JOLLA INSTITUTE FOR IMMUNOLOGY, USA <i>(11:45-11:55)</i> Implementation Effectiveness of a Community-Driven Vaccination Model at Boosting Immunization in Two Conflict-Affected Health Districts of Cameroon: A Quasi-Experimental Study Derrick Nebangwa , COMMUNITY-DRIVEN VACCINATION PROGRAMME (COVACC), CAMEROON
12:10-12:25	In situ cancer immunotherapy with modified MVdeltaC measles virus induces potent RIG-I-dependent tumor clearance and immune memory Frédéric Tangy , INSTITUT PASTEUR ONCOVITA, FRANCE	Structural Basis of 4G2-Induced Antibody-Dependent Enhancement in Flaviviruses Camilla Di Giulio , GLOBAL HEALTH INSTITUTE, EPFL, SWITZERLAND	Establishing a blood-stage Controlled Human Malaria Infection model in healthy Tanzanian adults with varying prior exposure to <i>P. falciparum</i> Omar Hassan , IFAKARA HEALTH INSTITUTE, TANZANIA <i>(12:10-12:20)</i>
12:25-12:40	Therapeutic HBV vaccine efficacy through ancestral mismatched T cell epitopes Nina Le Bert , DUKE-NUS MEDICAL SCHOOL, SINGAPORE	Rational design of live-attenuated West Nile virus vaccines that are non-transmissible by vector mosquitoes Gorben Pijlman , WAGENINGEN UNIVERSITY & RESEARCH, THE NETHERLANDS	An Intranasal Hemagglutinin Protein Booster After Intramuscular mRNA Vaccination Enhances Mucosal Immunity and Confers Protection Against Influenza Virus in Ferrets Seokchan Park , ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, USA
12:40-12:55	mRNA-Encoded HSV Monoclonal Antibody Based Immunotherapy Outperforms Acyclovir in a Murine Model of HSV-1 Encephalitis Sita Awasthi , UNIVERSITY OF PENNSYLVANIA, USA	Novel dengue virus non-structural protein vaccine that can prevent disease exacerbation caused by existing vaccines Kyoko Tsukiyama-Kohara , KAGOSHIMA UNIVERSITY, JAPAN	Divergent innate and humoral immune responses to 4CMenB vaccination in transgender individuals receiving gender-affirming hormone therapy Anthony Willems , CENTER FOR VACCINOLOGY (CEVAC), GHENT UNIVERSITY, BELGIUM

ISV ANNUAL CONGRESS 2026 • PROGRAMME

12:55-14:30	LUNCH • sponsored by GPN VACCINES	ATRIUM
13:30-14:30	CANADIAN VACCINE R&D SPOTLIGHT • sponsored by THE NRC	OKAPI
	Opening Remarks and Canada's Life Sciences and Commercialization Strategy Lakshmi Krishnan, NATIONAL RESEARCH COUNCIL (NRC) CANADA Advancing vaccine manufacturing platforms for rapid response to global health emergency Amine Kamen, MCGILL UNIVERSITY Canada's Public Health Agency Canada – From surveillance to vaccine preparedness Celia Lourenco, PUBLIC HEALTH AGENCY CANADA Stable CHO pools as a platform for rapid vaccine antigen manufacturing Yves Durocher, NATIONAL RESEARCH COUNCIL (NRC) CANADA	
14:00-15:30	POSTER SESSION 2 • sponsored by Merck Sharp & Dohme LLC	ATRIUM
14:30-15:30	ISV ANNUAL GENERAL MEETING	GORILLA 3
15:30-16:00	COFFEE BREAK • sponsored by VAXXAS	ATRIUM
16:00-17:50	PLENARY SESSION 4: Systems Vaccinology	OKAPI
	SESSION CHAIRS: Danilo Casimiro, SANOFI VACCINES R & D, USA Shan Lu, WORCESTER HIV VACCINE, USA	
16:00-16:25	Complexity from Simplicity: Using Systems Immunology to Define Conserved Innate Immune Mechanisms Mediating Diverse Effector Responses to Vaccines Jeffrey Tomalka, EMORY UNIVERSITY SCHOOL OF MEDICINE, USA	
16:25-16:50	Artificial Intelligence and Machine Learning (AI/ML) in the development of mRNA vaccines Fernando Ulloa-Montoya, SANOFI, FRANCE	
16:50-17:05	Induction of HIV broadly neutralizing antibodies by human vaccination Isabel Baken, AMSTERDAM UMC, THE NETHERLANDS	
17:05-17:20	Genome-guided identification and validation of novel T-cell vaccine targets for cross-species malaria protection Carla Proietti, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA	
17:20-17:35	Novel DNA Delivery Method Using Lipid Nanoparticles Induces Durable Polyfunctional Immune Responses with Tier2 Neutralizing Antibody and Cytotoxic CD8 T Cells Barbara Felber, NCI/NIH, USA	
17:35-17:50	Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates Kai Dallmeier, KU LEUVEN, BELGIUM	
18:30-23:00	GALA DINNER	MARBLE HALL

WEDNESDAY, 14 OCTOBER 2026

08:00-08:30	WELCOME COFFEE • sponsored by SpyBiotech	ATRIUM
08:30-09:00	KEYNOTE SPEAKER	OKAPI
	SESSION CHAIR: Isabel Leroux-Roels, UNIVERSITY OF GHENT, BELGIUM From Global Partnerships to Local Impact: Strengthening Vaccine Innovation Laura Palomares, INSTITUTO DE BIOTECNOLOGÍA UNAM, MEXICO	
09:00-10:35	PLENARY SESSION 5: One Health and Pandemic Preparedness	OKAPI
	SESSION CHAIRS: Albert Osterhaus, UNIVERSITY OF VETERINARY MEDICINE, GERMANY Laura Palomares, INSTITUTO DE BIOTECNOLOGÍA UNAM, MEXICO	
09:00-09:25	Active and Passive Mucosal Immunization Strategies for Improved Pandemic Preparedness Matthew Miller, MCMaster UNIVERSITY, CANADA	
09:25-09:50	Antigenic evolution of H5 viruses and subtype-wide H5 vaccine development Mathilde Richard, ERASMUS MC, THE NETHERLANDS	

9:50-10:05	Safety of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in Tanzanian adults: an open-label, non-randomised phase 1 clinical trial Latipha Mohamed, IFAKARA HEALTH INSTITUTE, TANZANIA		
10:05-10:20	Single-visit rabies vaccination with a simian adenovirus vector elicits durable neutralising antibody responses indicating likely protection for >2 years: mid-term results from the RAB002 phase Ib/II clinical trial Alexander Douglas, UNIVERSITY OF OXFORD, UNITED KINGDOM		
10:20-10:35	Design, Development and Characterisation of Multivalent mRNA-LNP Vaccine Candidates for Mpox Hapiloe Maranyane-Tshililo, AFRIGEN BIOLOGICS & VACCINES, SOUTH AFRICA		
10:35-11:00	COFFEE BREAK • sponsored by CanSino Biologics		
	ATRIUM		
11:00-12:35	CONCURRENT SESSION 7	CONCURRENT SESSION 8	CONCURRENT SESSION 9
	OKAPI	GORILLA 1	GORILLA 3
	Vaccine Confidence	Emerging Infections	Veterinary Vaccines
	SESSION CHAIRS: Linda Klavinskis, KING'S COLLEGE LONDON, UNITED KINGDOM Frédéric Tangy, INSTITUT PASTEUR ONCOVITA, FRANCE	SESSION CHAIRS: Jeffrey Ulmer, TECHIMMUNE LLC, USA Branka Grubor-Bauk, ADELAIDE UNIVERSITY, AUSTRALIA	SESSION CHAIRS: Amine Kamen, MCGILL UNIVERSITY, CANADA Denise Doolan, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA
11:00-11:25	The State of Vaccine Confidence in 2026 Emilie Karafillakis, LONDON INSTITUTE FOR TROPICAL MEDICINE AND HYGIENE, UNITED KINGDOM	Preclinical and clinical development of a cellular immunity-based Covid-19 vaccine Helton Santiago, FEDERAL UNIVERSITY OF MINAS GERAIS, BRAZIL	Co-Infections and Immunomodulation: Hurdles and Drivers in Bovine Vaccinology ALEJANDRA CAPOZZO, UNIVERSIDAD ABIERTA INTERAMERICANA, ARGENTINA
11:25-11:50	Beyond Vaccine Hesitancy: Understanding and Rebuilding Trust in Vaccination in Complex Social Ecosystems Ève Dubé, LAVAL UNIVERSITY, CANADA	Safety and immunogenicity of EuHZV, an ECLS-based recombinant herpes zoster vaccine: a first-in-human Phase 1 study in adults aged 50–69 years Howard Her, EUBIOLOGICS CO., LTD, SOUTH KOREA	Developing Next Generation Broad-Spectrum Bacterial Vaccines Tim Hirst AND Chole Gates, GPN VACCINES, AUSTRALIA
11:50-12:05	Bridging the Mpox Vaccine Uptake Gap in Africa: Determinants of Acceptance and Hesitancy from a Systematic Review and Meta-Analysis Charles Ibeneme, TEXILA AMERICA UNIVERSITY ZAMBIA CAMPUS, ZAMBIA	Stabilized henipavirus fusion glycoproteins induce strong serum neutralizing antibody responses against of authentic virus and inform future vaccine design. Haye Nijhuis, AMSTERDAM UMC, THE NETHERLANDS	Selection and characterization of a contemporary respiratory syncytial virus subtype B strain for use in Controlled Human Infection Model (CHIM) studies Albert Osterhaus, UNIVERSITY OF VETERINARY MEDICINE HANNOVER, GERMANY
12:05-12:20	Panel Discussion MODERATOR: Michael Schotsaert, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, USA PANELISTS:	CD4+ T cell-mediated immunity protects from VSV-SUD lethal challenge in a mouse model of Sudan virus infection Lara Kelchtermans, KU LEUVEN, BELGIUM	Development of a vaccine against deadly elephant endotheliotropic herpesvirus Xander De Haan, UTRECHT UNIVERSITY, THE NETHERLANDS
12:20-12:35	Emilie Karafillakis, LONDON INSTITUTE FOR TROPICAL MEDICINE AND HYGIENE, UNITED KINGDOM Ève Dubé, LAVAL UNIVERSITY, CANADA Chunlin Xin, CANSINO BIOLOGICS, PEOPLE'S REPUBLIC OF CHINA Igor Smolenov, ARCTURUS THERAPEUTICS, USA	Characterization of the immune response to Fusobacterium nucleatum, an emerging pathogen associated with adverse pregnancy outcomes Tracy Lee, BC CANCER RESEARCH INSTITUTE, CANADA	Evaluation of the protective efficacy of foot-and-mouth disease vaccines against O/CATHAY topotype virus in pigs Yoon Hee Lee, ANIMAL AND PLANT QUARANTINE AGENCY, SOUTH KOREA
12:35-14:00	LUNCH • sponsored by HUMAN VACCINES & IMMUNOTHERAPEUTICS (HVI) and EXPERT REVIEW OF VACCINES (ERV)		
	ATRIUM		
13:00-14:00	THE CAREER LAB: MANY PATHS, SHARED PURPOSE An interactive workshop bringing together people across career stages to share experiences, exchange candid advice and lessons learned, and explore your next move towards a meaningful career in the vaccine ecosystem. Linda Lua, THE UNIVERSITY OF QUEENSLAND & THE GROWTH IMPACT, AUSTRALIA		
	OKAPI		
14:00-14:30	AWARD CEREMONY		
	OKAPI		

14:30-14:55	ISV PAPER OF THE YEAR (VIRTUAL)	OKAPI
SESSION CHAIR: Sita Awasthi, UNIVERSITY OF PENNSYLVANIA, USA A natural experiment on the effect of herpes zoster vaccination on dementia Pascal Geldsetzer, STANFORD UNIVERSITY, USA		
14:55-15:50	PLENARY SESSION 6: Challenge Studies	OKAPI
SESSION CHAIRS: Isabel Leroux-Roels, UNIVERSITY OF GHEENT, BELGIUM Baik-Lin Seong, YONSEI UNIVERSITY, SOUTH KOREA		
14:55-15:20	The Flu Air Shedding and Immune Monitoring (FLAIM) study, the first controlled human infection study at Vaccinopolis, Belgium Joren Raymenants , UNIVERSITY OF ANTWERP, BELGIUM	
15:20-15:35	Predicting West Nile Virus Outcomes: Insights and Limitations from Murine and Avian Models Byron Martina , ARTEMIS BIOSERVICES, THE NETHERLANDS	
15:35-15:50	SARS-CoV-2 humoral waning kinetics are reversed by inactivated vaccine boosting, restoring functional responses, durability and breadth Rafael Medina , EMORY UNIVERSITY SCHOOL OF MEDICINE, USA	
15:50-16:00	CLOSING SESSION & INTRODUCTION TO THE 2027 ISV ANNUAL CONGRESS	OKAPI
Manon Cox, NEXTWAVE BIO / ISV PRESIDENT, USA Lakshmi Krishnan, NATIONAL RESEARCH COUNCIL (NRC), CANADA		
16:20-17:20	POST CONGRESS – A PANEL DISCUSSION BY BAVARIAN NORDIC New Insights on Mpox: Implications for Public Health and Clinical Practice	GORILLA 3

PARTNERS



DIAMOND

sanofi

GOLD



SILVER



OTHER SUPPORT

